Universal Beteiligungs und Servicegesellschaft mbH Takes $29.99 Million Position in Insulet Co. (NASDAQ:PODD)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 114,883 shares of the medical instruments supplier's stock, valued at approximately $29,993,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.16% of Insulet at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in shares of Insulet in the 4th quarter worth $36,000. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Insulet by 30.1% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier's stock worth $2,192,000 after buying an additional 1,942 shares during the period. Jennison Associates LLC boosted its holdings in Insulet by 21.8% in the 4th quarter. Jennison Associates LLC now owns 158,342 shares of the medical instruments supplier's stock worth $41,338,000 after buying an additional 28,375 shares during the period. Vontobel Holding Ltd. boosted its holdings in shares of Insulet by 4.3% during the 4th quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier's stock valued at $633,000 after purchasing an additional 100 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Insulet during the 4th quarter valued at about $9,822,000.

Insider Transactions at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president now directly owns 23,180 shares in the company, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Stock Performance

NASDAQ:PODD traded up $0.65 during mid-day trading on Friday, hitting $324.50. The company's stock had a trading volume of 960,683 shares, compared to its average volume of 709,973. Insulet Co. has a 1 year low of $172.07 and a 1 year high of $329.33. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market cap of $22.84 billion, a price-to-earnings ratio of 56.05, a PEG ratio of 3.62 and a beta of 1.26. The business's fifty day moving average is $276.61 and its two-hundred day moving average is $271.69.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.73 EPS. Analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective for the company. Citigroup reaffirmed a "buy" rating and issued a $380.00 price target (up previously from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Stifel Nicolaus increased their price target on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Finally, Piper Sandler increased their price target on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $313.78.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.